MMED financial statements
The full income statement, balance sheet, and cash-flow statement for MiniMed Group Inc. (MMED), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2026 | FY2025 | FY2024 |
|---|---|---|---|---|
| Income Statement | as ofApr 24 ’26 | as ofApr 25 ’25 | as ofApr 26 ’24 | |
| Revenue | 3.10B+14.3% | 2.71B+10.0% | 2.47B | |
| 1.68B+9.9% | 1.53B+6.4% | 1.44B | ||
| Cost of revenue | 1.42B+19.8% | 1.19B+15.0% | 1.03B | |
| Research & development | 448M+2.8% | 436M-0.2% | 437M | |
| Selling, general & administrative | 1.18B+9.5% | 1.08B+2.2% | 1.06B | |
| Amortization of intangibles | 26.0M-10.3% | 29.0M-12.1% | 33.0M | |
| Provision for credit losses | 28.0M+33.3% | 21.0M-4.5% | 22.0M | |
| Operating income | -190M-30.1% | -146M-111.6% | -69.0M | |
| Other non-operating income | 1.00M+200.0% | -1.00M+0.0% | -1.00M | |
| Pre-tax income | -189M-28.6% | -147M-110.0% | -70.0M | |
| Income tax | 128M+146.2% | 52.0M+36.8% | 38.0M | |
| -317M-48.8% | -213M-90.2% | -112M | ||
| Net income to non-controlling interest | 16.0M+6.7% | 15.0M+200.0% | 5.00M | |
| -$1.30-54.8% | -$0.84-90.9% | -$0.44 | ||
| EPS (basic) | -$1.30-54.8% | -$0.84-90.9% | -$0.44 | |
| Weighted-avg shares (basic) | 257M+1.5% | 253M+0.0% | 253M | |
| Weighted-avg shares (diluted) | 257M+1.5% | 253M+0.0% | 253M | |
| Balance Sheet | as ofApr 24 ’26 | as ofApr 25 ’25 | as ofApr 26 ’24 | |
| 1.35B+43.6% | 939M | — | ||
| Cash & equivalents | 298M+2609.1% | 11.0M-79.6% | 54.0M | |
| Accounts receivable | 200M-64.9% | 570M | — | |
| Inventory | 341M+9.6% | 311M | — | |
| Other current assets | 54.0M+12.5% | 48.0M | — | |
| 4.63B+10.2% | 4.20B | — | ||
| Property, plant & equipment | 711M+0.7% | 706M | — | |
| Operating lease right-of-use | 52.0M-21.2% | 66.0M | — | |
| Goodwill | 2.26B+0.0% | 2.25B | — | |
| Intangible assets | 107M-18.9% | 132M | — | |
| Deferred tax assets | 61.0M+221.1% | 19.0M | — | |
| Other non-current assets | 147M-2.0% | 150M | — | |
| 702M-1.1% | 710M | — | ||
| Accounts payable | 163M-20.5% | 205M | — | |
| Deferred revenue | 15.0M+36.4% | 11.0M | — | |
| Current lease liability | 8.00M-27.3% | 11.0M | — | |
| Other current liabilities | — | 271M | — | |
| 1.02B+17.0% | 871M | — | ||
| Deferred revenue (non-current) | 4.00M+33.3% | 3.00M | — | |
| Non-current lease liability | 45.0M-19.6% | 56.0M | — | |
| Operating lease liability (total) | 53.0M | — | — | |
| Other non-current liabilities | 317M+95.7% | 162M | — | |
| 3.61B+8.4% | 3.33B-3.4% | 3.45B | ||
| Preferred stock | 0.00 | 0.00 | — | |
| Common stock | 3.00M | 0.00 | — | |
| Additional paid-in capital | 3.74B | 0.00 | — | |
| Retained earnings | -116M | 0.00 | — | |
| Accumulated other comprehensive income | -12.0M-500.0% | 3.00M | — | |
| Non-controlling interest | 0.00 | 0.00 | — | |
| Total equity incl. non-controlling | 3.61B+8.4% | 3.33B | — | |
| Total liabilities & equity | 4.63B+10.2% | 4.20B | — | |
| Common shares issued | 281M | — | — | |
| Common shares outstanding | 281M | — | — | |
| Shares outstanding (cover) | 281M | — | — | |
| Cash Flow | as ofApr 24 ’26 | as ofApr 25 ’25 | as ofApr 26 ’24 | |
| -197M-240.7% | 140M+241.5% | 41.0M | ||
| Depreciation & amortization | 156M+9.1% | 143M+10.9% | 129M | |
| Intangible amortization | 26.0M-10.3% | 29.0M-12.1% | 33.0M | |
| Share-based compensation | 46.0M+12.2% | 41.0M+7.9% | 38.0M | |
| Deferred income taxes | -50.0M-2400.0% | -2.00M-166.7% | 3.00M | |
| Change in inventory | 29.0M+52.6% | 19.0M+480.0% | -5.00M | |
| -233M-20.7% | -193M-22.9% | -157M | ||
| Capital expenditure | 223M+15.5% | 193M+30.4% | 148M | |
| Free cash flow | -420M-692.5% | -53.0M+50.5% | -107M | |
| Acquisitions | 0.00 | 0.00 | 0.00 | |
| Purchases of investments | 0.00 | 0.00-100.0% | 5.00M | |
| Sales/maturities of investments | 0.00 | 0.00-100.0% | 11.0M | |
| Other investing activities | 10.0M | 0.00-100.0% | 14.0M | |
| 716M+7060.0% | 10.0M-91.1% | 112M | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | |
| Other financing activities | 0.00+100.0% | -2.00M | 0.00 | |
| Net change in cash | 287M+767.4% | -43.0M-975.0% | -4.00M | |
| Income taxes paid | 2.00M | 0.00 | 0.00 | |
| Valuation Ratios | as ofApr 24 ’26 | as ofApr 25 ’25 | as ofApr 26 ’24 | |
| Market cap | 3.71B | — | — | |
| P/S | 1.2× | — | — | |
| P/B | 1.0× | — | — | |
| Source filing | 10-K | 10-K | 10-K |
About this data
Source: MMED’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all MMED filings on SEC EDGAR → Not investment advice.